SCHEMBL18349673

SCHEMBL18349673

CC[C@H]1O[C@@H](n2cnc3c(N)ncnc32)[C@@H](OCCOCCN2C(=O)c3ccccc3C2=O)C1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA1 P30542 5/20 0.49
▸ EHMT1 Q9H9B1 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ DPP4 P27487 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ SLC28A1 O00337 1/20 0.46
▸ MAP3K7 O43318 1/20 0.46
▸ SLC28A2 O43868 1/20 0.46
▸ GAPDH P04406 1/20 0.46
▸ ADORA3 P0DMS8 1/20 0.46
▸ MAPK1 P28482 1/20 0.46
▸ ADORA2A P29274 1/20 0.46
▸ ADORA2B P29275 1/20 0.46
▸ STAT6 P42226 1/20 0.46
▸ PI4KA P42356 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ PI4K2B Q8TCG2 1/20 0.46
▸ DOT1L Q8TEK3 1/20 0.46
▸ SLC29A1 Q99808 1/20 0.46
▸ PI4K2A Q9BTU6 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18349670 0.93 ADORA1 (0.59) ADORA1SMN1; SMN2DPP4MEN1SLC28A1
SCHEMBL16392746 0.93 ADORA1 (0.59) ADORA1SMN1; SMN2DPP4MEN1SLC28A1
SCHEMBL18349664 0.91 ADORA1 (0.49) ADORA1EHMT1SMN1; SMN2DPP4MEN1
SCHEMBL18349909 0.84 EHMT1 (0.50) ADORA1EHMT1SMN1; SMN2DPP4MEN1
SCHEMBL18349672 0.84 ADORA1 (0.55) ADORA1EHMT1SMN1; SMN2DPP4MEN1
SCHEMBL16392614 0.83 ADORA1 (0.59) ADORA1SMN1; SMN2DPP4MEN1SLC28A1
SCHEMBL22559825 0.83 ADORA1 (0.59) ADORA1SMN1; SMN2DPP4MEN1SLC28A1
SCHEMBL16393084 0.83 ADORA1 (0.59) ADORA1SMN1; SMN2DPP4MEN1SLC28A1
SCHEMBL25966341 0.81 ADORA1 (0.61) ADORA1EHMT1SMN1; SMN2DPP4MEN1
SCHEMBL18349674 0.79 KDM4E (0.45) MEN1KMT2ATAS1R3TAS1R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160376585-A1 OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION BANK OF AMERICA, N.A. 2016-12-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160376585-A1 OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION IGF2R, IRS1, INSR ADORA1 500/4885EHMT1 3576/4885SMN1; SMN2 1128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback